Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertapenem vs piperacillin/tazobactam for diabetic foot infection in Chinese adults
CTR20131161Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ertapenem in diabetic foot infection (DFI) (2 arms), sponsored by Merck & Co. Primary endpoint: Proportion of patients with a good clinical response at discontinuation of IV therapy (DCIV). Started Apr 2014; status: active.
02
Drugs
ertapenem
03
Conditions
diabetic foot infection (DFI)
Beyond the preview
Go deeper on CTR20131161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131161.